Treatment of Oral Thrush in NPO Patients

Primary Treatment Approach

• The Infectious Diseases Society of America recommends IV fluconazole 400 mg (6 mg/kg) daily as the preferred first-line treatment for NPO patients, with echinocandins as equally effective alternatives 1
• Echinocandins, including micafungin 150 mg daily, caspofungin 70 mg loading dose then 50 mg daily, and anidulafungin 200 mg daily, are recommended alternatives for NPO patients 1

Treatment Duration and De-escalation

• The Infectious Diseases Society of America recommends continuing IV therapy for 14-21 days for esophageal involvement, and 7-14 days for isolated oropharyngeal thrush 1
• De-escalation to oral fluconazole 200-400 mg daily is recommended once the patient can tolerate oral intake 1

Important Clinical Considerations

• The presence of dysphagia or odynophagia in addition to visible oral thrush suggests esophageal involvement, requiring a higher fluconazole dose (400 mg) and longer duration (14-21 days) 3

Management of Refractory Disease

• IV voriconazole 200 mg (3 mg/kg) twice daily for 14-21 days is recommended for patients who fail to respond to initial IV fluconazole 1
• Continuing echinocandin therapy is recommended for patients who fail to respond to initial IV fluconazole 1

Common Pitfalls to Avoid

• Underdosing, particularly for esophageal involvement or severe disease, should be avoided, with a recommended dose of 400 mg daily 1
• Forgetting to disinfect dentures can lead to reinfection, and should be done in addition to antifungal therapy 1

Special Populations

• For HIV-infected patients, initiating or optimizing antiretroviral therapy can reduce recurrence risk, and chronic suppressive therapy with fluconazole 100-200 mg three times weekly may be considered for recurrent infections 1